Azenta initiated with a Hold at TD Cowen

TD Cowen initiated coverage of Azenta (AZTA) with a Hold rating and $50 price target The company’s core sample management solutions and multiomics franchises are competitive but facing political headwinds amid the China tariffs and National Institutes of Health funding uncertainty, which is compounded by the lagging B Medical vaccine cold chain storage segment, the analyst tells investors in a research note. The firm believes Azenta’s restructuring initiatives to streamline operational toward higher margin segments will take time.